Recent News

• 06.08.2026 - Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
• 06.01.2026 - Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
• 06.01.2026 - Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland
• 05.27.2026 - Cytokinetics to Participate in June Investor Conferences

Recent Filings

• 06.01.2026 - 144 Report of proposed sale of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities